ECSP088477A - Derivados de 3-alquilazetidina sustituidos con heterociclos - Google Patents
Derivados de 3-alquilazetidina sustituidos con heterociclosInfo
- Publication number
- ECSP088477A ECSP088477A EC2008008477A ECSP088477A ECSP088477A EC SP088477 A ECSP088477 A EC SP088477A EC 2008008477 A EC2008008477 A EC 2008008477A EC SP088477 A ECSP088477 A EC SP088477A EC SP088477 A ECSP088477 A EC SP088477A
- Authority
- EC
- Ecuador
- Prior art keywords
- treatment
- disorders
- useful
- compounds
- receptor
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 206010014612 Encephalitis viral Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 201000002498 viral encephalitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos novedosos de la fórmula estructural (I) son antagonistas y/o agonistas inversos del receptor canabinoide-1 (CB1) y son útiles en el tratamiento, prevención y supresión de enfermedades mediadas por el receptor CB1. Los compuestos de la presente invención son útiles como fármacos que actúan a nivel central en el tratamiento de psicosis, deficiencias de la memoria, trastornos cognitivos, enfermedad de Alzheimer, migraña, neuropatía, trastornos neuroinflamatorios que incluyen esclerosis múltiple y síndrome de Guillain-Barré y las secuelas inflamatorias de la encefalitis vírica, accidentes vasculares cerebrales, y traumatismo craneal, trastornos de ansiedad, estrés, epilepsia, enfermedad de Parkinson, trastornos del movimiento, y esquizofrenia. Los compuestos también son útiles para el tratamiento de trastornos de abuso de sustancias, para el tratamiento de obesidad o trastornos de la alimentación, así como para el tratamiento de asma, estreñimiento, pseudo-obstrucción intestinal crónica, y cirrosis hepática.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74018305P | 2005-11-28 | 2005-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP088477A true ECSP088477A (es) | 2008-06-30 |
Family
ID=37779312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2008008477A ECSP088477A (es) | 2005-11-28 | 2008-05-27 | Derivados de 3-alquilazetidina sustituidos con heterociclos |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1954692A1 (es) |
| KR (1) | KR20080073721A (es) |
| AR (1) | AR058199A1 (es) |
| BR (1) | BRPI0619018A2 (es) |
| CR (1) | CR10014A (es) |
| DO (1) | DOP2006000261A (es) |
| EC (1) | ECSP088477A (es) |
| IL (1) | IL191586A0 (es) |
| MA (1) | MA30086B1 (es) |
| NO (1) | NO20082919L (es) |
| PE (1) | PE20070647A1 (es) |
| RU (1) | RU2008126248A (es) |
| SV (1) | SV2009002917A (es) |
| TW (1) | TW200804317A (es) |
| WO (1) | WO2007062193A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CA2703465A1 (en) * | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Synthesis and crystalline forms of cb-1 antagonist/inverse agonist |
| WO2012031220A2 (en) | 2010-09-03 | 2012-03-08 | University Of Florida Research Foundation, Inc. | Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2805818B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| FR2805810B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| FR2805817B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| KR20060019587A (ko) * | 2003-06-11 | 2006-03-03 | 머크 앤드 캄파니 인코포레이티드 | 치환된 3-알킬 및 3-알케닐 아제티딘 유도체 |
| US20090306037A1 (en) * | 2005-05-02 | 2009-12-10 | Merck & Co., Inc. | Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity |
-
2006
- 2006-11-20 AR ARP060105076A patent/AR058199A1/es unknown
- 2006-11-22 RU RU2008126248/04A patent/RU2008126248A/ru not_active Application Discontinuation
- 2006-11-22 TW TW095143274A patent/TW200804317A/zh unknown
- 2006-11-22 WO PCT/US2006/045328 patent/WO2007062193A1/en not_active Ceased
- 2006-11-22 EP EP06838347A patent/EP1954692A1/en not_active Withdrawn
- 2006-11-22 BR BRPI0619018A patent/BRPI0619018A2/pt not_active IP Right Cessation
- 2006-11-22 KR KR1020087012880A patent/KR20080073721A/ko not_active Withdrawn
- 2006-11-23 PE PE2006001495A patent/PE20070647A1/es not_active Application Discontinuation
- 2006-11-23 DO DO2006000261A patent/DOP2006000261A/es unknown
-
2008
- 2008-05-20 IL IL191586A patent/IL191586A0/en unknown
- 2008-05-22 CR CR10014A patent/CR10014A/es not_active Application Discontinuation
- 2008-05-27 EC EC2008008477A patent/ECSP088477A/es unknown
- 2008-05-28 SV SV2008002917A patent/SV2009002917A/es not_active Application Discontinuation
- 2008-06-25 MA MA31075A patent/MA30086B1/fr unknown
- 2008-06-27 NO NO20082919A patent/NO20082919L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200804317A (en) | 2008-01-16 |
| WO2007062193A1 (en) | 2007-05-31 |
| CR10014A (es) | 2008-07-29 |
| IL191586A0 (en) | 2008-12-29 |
| EP1954692A1 (en) | 2008-08-13 |
| AR058199A1 (es) | 2008-01-23 |
| PE20070647A1 (es) | 2007-08-11 |
| SV2009002917A (es) | 2009-02-19 |
| RU2008126248A (ru) | 2010-01-10 |
| MA30086B1 (fr) | 2008-12-01 |
| NO20082919L (no) | 2008-08-27 |
| DOP2006000261A (es) | 2007-07-15 |
| BRPI0619018A2 (pt) | 2016-11-29 |
| KR20080073721A (ko) | 2008-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP056207A (es) | Derivados de 3-alquil y 3-alquenilazetidina sustituidos | |
| ECSP045289A (es) | Amidas sustituidas | |
| DE60316829D1 (de) | Substituierte furoä2,3-büpyridin derivate | |
| DE60334787D1 (de) | Substituierte amide | |
| EP1492784A4 (en) | SUBSTITUTED 2,3-DIPHENYLPYRIDINES | |
| ATE501151T1 (de) | Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatoren | |
| WO2003082190A3 (en) | Spirocyclic amides as cannabinoid receptor modulators | |
| WO2008024284A3 (en) | Sulfonylated piperazines as cannabinoid-1 receptor modulators | |
| WO2003063781A3 (en) | Substituted imidazoles as cannabinoid receptor modulators | |
| WO2005027837A3 (en) | Substituted sulfonamides | |
| WO2004029204A3 (en) | Substituted pyrimidines | |
| WO2004058145A3 (en) | Substituted amides | |
| WO2003086288A3 (en) | Bicyclic amides | |
| ATE452890T1 (de) | Substituierte naphthyridinonderivate | |
| WO2007136607A3 (en) | Substituted esters as cannabinoid-1 receptor modulators | |
| DOP2019000126A (es) | Pirrolopirimidinas como potenciadores de cftr | |
| CR10014A (es) | Derivados de 3-alquilazetidina sustituidos con heterociclos. | |
| JP2019535799A5 (es) | ||
| WO2007064566A3 (en) | Heterocycle-substituted 3-alkyl azetidine derivatives | |
| IL192240A0 (en) | Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists | |
| WO2014014698A3 (en) | Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof | |
| DOP2004001060A (es) | Compuestos moduladores de cb1 |